OVARIO: The phase 2, single-arm, open-label study of maintenance therapy with niraparib + bevacizumab in patients with advanced ovarian cancer following response on frontline platinum-based chemotherapy.

Authors

Joanie M. Hope

Alaska Women's Cancer Care, Anchorage, AK

Joanie M. Hope , Jian Chen , Marisa Wainszelbaum , Divya Gupta

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

QUADRA: A phase 2, open-label, single-arm study to evaluate niraparib in patients (pts) with relapsed ovarian cancer (ROC) who have received ≥3 prior chemotherapy regimens.

First Author: Kathleen N. Moore

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).

First Author: Elena Ioana Braicu

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.

First Author: Debra L. Richardson

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial.

First Author: JUNG-YUN LEE